| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...621772L |
| P356 | DOI | 10.1371/JOURNAL.PONE.0021772 |
| P932 | PMC publication ID | 3128605 |
| P698 | PubMed publication ID | 21747955 |
| P5875 | ResearchGate publication ID | 51484563 |
| P50 | author | Ana S F Oliveira | Q84542194 |
| Paul P Tak | Q89865007 | ||
| P2093 | author name string | Richard Horuk | |
| Maria C Lebre | |||
| Clarissa E Vergunst | |||
| Kris A Reedquist | |||
| Tim Wyant | |||
| Saïda Aarrass | |||
| Ivy Y K Choi | |||
| P2860 | cites work | Chemokine blockade: a new era in the treatment of rheumatoid arthritis? | Q24800857 |
| Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice | Q57019206 | ||
| Infiltrated Neutrophils Acquire Novel Chemokine Receptor Expression and Chemokine Responsiveness in Chronic Inflammatory Lung Diseases | Q62555626 | ||
| The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines | Q71778731 | ||
| Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity | Q73092605 | ||
| CXCR3 and CCR5 ligands in rheumatoid arthritis synovium | Q73352970 | ||
| RANTES expression and contribution to monocyte chemotaxis in arthritis | Q77359406 | ||
| Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis | Q80229816 | ||
| Is CCR2 the right chemokine receptor to target in rheumatoid arthritis? | Q81514399 | ||
| Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker | Q81517383 | ||
| MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study | Q84966679 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease | Q33516229 | ||
| The role of chemokine receptors in primary, effector, and memory immune responses | Q33932742 | ||
| Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis | Q34129985 | ||
| Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis | Q35553008 | ||
| Chemokines in joint disease: the key to inflammation? | Q35553416 | ||
| Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis | Q35636896 | ||
| Chemokines and their receptors in rheumatoid arthritis: future targets? | Q36063483 | ||
| The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis | Q36096959 | ||
| Cells of the synovium in rheumatoid arthritis. Macrophages | Q36465497 | ||
| The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases | Q37465013 | ||
| Chemokine receptor antagonists: Part 1. | Q37481238 | ||
| Chemokine receptor antagonists: part 2. | Q37481304 | ||
| CCR1 antagonists: what have we learned from clinical trials | Q37763962 | ||
| A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis | Q39763545 | ||
| Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial | Q39850979 | ||
| CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. | Q42943397 | ||
| Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate | Q42956746 | ||
| Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue | Q43184367 | ||
| Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis | Q43607170 | ||
| Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. | Q45999111 | ||
| Overcoming hurdles in developing successful drugs targeting chemokine receptors | Q46441158 | ||
| Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. | Q47393101 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | e21772 | |
| P577 | publication date | 2011-07-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis | |
| P478 | volume | 6 |
| Q54170357 | CCR2 Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in Rheumatoid Arthritis. |
| Q24701793 | CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis |
| Q47113676 | CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis |
| Q33805455 | Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells |
| Q91199065 | Chemokines in rheumatic diseases: pathogenic role and therapeutic implications |
| Q33672477 | Cross-desensitization of CCR1, but not CCR2, following activation of the formyl peptide receptor FPR1. |
| Q48129259 | Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases. |
| Q37261899 | Effects of interleukin-1β and tumor necrosis factor-α on macrophage inflammatory protein-3α production in synovial fibroblast-like cells from human temporomandibular joints |
| Q48268499 | Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial. |
| Q53309302 | European League against rheumatism - selected presentation and poster a highlights June 11th to 13th 2013. |
| Q37331952 | Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis |
| Q39619506 | IL-17A and IL-25: therapeutic targets for allergic and exacerbated asthmatic disease |
| Q38434343 | Identifying key genes in rheumatoid arthritis by weighted gene co-expression network analysis |
| Q48297258 | Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis. |
| Q38618883 | Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review |
| Q37432097 | International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors |
| Q38844780 | Macrophage heterogeneity in the context of rheumatoid arthritis. |
| Q56889038 | Modulating Macrophage Polarization through CCR2 Inhibition and Multivalent Engagement |
| Q64107980 | Neutrophils Induce a Novel Chemokine Receptors Repertoire During Influenza Pneumonia |
| Q45950376 | Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis. |
| Q89576490 | Ontology and Function of Fibroblast-Like and Macrophage-Like Synoviocytes: How Do They Talk to Each Other and Can They Be Targeted for Rheumatoid Arthritis Therapy? |
| Q38083321 | Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012. |
| Q38196934 | Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4. |
| Q38632834 | Recommendations for the development and validation of flow cytometry-based receptor occupancy assays |
| Q90642824 | Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis |
| Q38647749 | Successes and failures of chemokine-pathway targeting in rheumatoid arthritis |
| Q58712847 | T Cells That Help B Cells in Chronically Inflamed Tissues |
| Q38615369 | T cell specific Cxcr5 deficiency prevents rheumatoid arthritis |
| Q36527922 | Targeting of CCL2-CCR2-Glycosaminoglycan Axis Using a CCL2 Decoy Protein Attenuates Metastasis through Inhibition of Tumor Cell Seeding |
| Q26774681 | The Interplay Between Monocytes/Macrophages and CD4(+) T Cell Subsets in Rheumatoid Arthritis |
| Q24337078 | The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization |
| Q41945153 | The multiple chemokine-binding bovine herpesvirus 1 glycoprotein G (BHV1gG) inhibits polymorphonuclear cell but not monocyte migration into inflammatory sites. |
| Q92496416 | The role of CCR1 and therapeutic effects of anti-CCL3 antibody in herpes simplex virus-induced Behçet's disease mouse model |
| Q43239473 | Tumor necrosis factor α- and interleukin-1β-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1. |
| Q24633598 | Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis |
| Q42326321 | What is the future of CCR5 antagonists in rheumatoid arthritis? |
Search more.